Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Clinical trial NCT02013791 · TERMINATED

Trial details

NCT number: NCT02013791
Sponsor: Allergan
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Dry Eye Syndromes

Start date: 2014-04-29
Primary completion: 2017-04-12
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.